Pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma
Please note that following on from information provided to NICE by the company in January 2012, the appraisal of Pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID368] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
Referral date 01 September 2010
Topic area
  • Cancer
Description

Scoped within Batch 13

Provisional Schedule

Closing date for invited submissions / evidence submission: 18 January 2012
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Executive Lead: Peter Littlejohns
Project manager: Rebecca Pye
Technical Lead: Pall Jonsson

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in January 2012, the appraisal of Pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID368] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
17 February 2012 Following an update on the regulatory status of the technology which has received a negative CHMP opinion, the 25 April 2012 committee meeting discussion for this appraisal has been cancelled. We are monitoring this situation and will provide an update as soon as possible.
1 December 2011 We have received the latest regulatory timings for pralatrexate from the manufacturer, Allos Therapeutics, and are now able to update our timelines for the above appraisal. The first committee meeting will be held on 25 April 2012.
13 July 2011 Following an update from the manufacturer, Allos Therapeutics, on the regulatory timings for pralatrexate the 27 September 2011 committee meeting discussion for the above appraisal has been cancelled.

We will update this page with the new timings as soon as possible.

For further information on our processes and methods, please see our CHTE processes and methods manual